Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) CAO Kathryn Romano sold 750 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $267.60, for a total transaction of $200,700.00. Following the transaction, the chief accounting officer owned 22,366 shares in the company, valued at $5,985,141.60. This trade represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kathryn Romano also recently made the following trade(s):
- On Monday, February 9th, Kathryn Romano sold 12,500 shares of Krystal Biotech stock. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00.
Krystal Biotech Stock Performance
Shares of Krystal Biotech stock opened at $263.80 on Wednesday. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $298.30. The firm's 50-day simple moving average is $269.38 and its 200-day simple moving average is $216.90. The firm has a market cap of $7.71 billion, a PE ratio of 38.51 and a beta of 0.49.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The business had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. On average, equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on KRYS shares. Zacks Research lowered Krystal Biotech from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 5th. Weiss Ratings upgraded shares of Krystal Biotech from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, February 18th. HC Wainwright reissued a "buy" rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. TD Cowen reaffirmed a "buy" rating on shares of Krystal Biotech in a report on Friday, January 9th. Finally, Bank of America boosted their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a "buy" rating in a research report on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $326.25.
View Our Latest Stock Analysis on Krystal Biotech
Hedge Funds Weigh In On Krystal Biotech
Several hedge funds and other institutional investors have recently modified their holdings of the company. Soleus Capital Management L.P. grew its position in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock worth $126,870,000 after acquiring an additional 481,200 shares during the last quarter. Braidwell LP boosted its stake in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company's stock valued at $100,045,000 after purchasing an additional 327,067 shares during the period. Norges Bank acquired a new position in Krystal Biotech during the 4th quarter valued at about $70,159,000. William Blair Investment Management LLC raised its holdings in shares of Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company's stock valued at $92,783,000 after buying an additional 227,038 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Krystal Biotech by 2,078.9% during the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company's stock worth $54,147,000 after buying an additional 209,369 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
